Investigating heart disease prevention in people living with HIV
Official title: 1/2 REPRIEVE Extension for Trial Completion
Funded at Massachusetts General Hospital · NIH-11086817 · Data updated 2026-11-12
This study is looking at how statin medications might help people with HIV lower their risk of heart disease, and it's inviting a diverse group of participants to join in so we can learn more about keeping their hearts healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $2,903,944 |
| NIH project number | 5UG3HL164285-03 |
| Project ID | NIH-11086817 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are at risk for cardiovascular disease.
✕Less likely to help
Patients who are not living with HIV or those who do not have risk factors for cardiovascular disease may not benefit from this research.
What this research studies
This research focuses on understanding how statin therapy can help prevent cardiovascular disease (CVD) in individuals living with HIV. The ongoing REPRIEVE trial is examining the effects of statins on various risk factors associated with heart disease, aiming to provide valuable insights into effective prevention strategies. By enrolling a diverse group of participants from multiple countries, the study seeks to gather high-quality data that can inform future HIV care practices. Participants will undergo assessments to monitor their cardiovascular health and immune function over time.
Why it matters
Potential benefit: If successful, this research could lead to improved heart disease prevention strategies for people living with HIV, ultimately enhancing their overall health and longevity.
How similar studies have gone: Previous research has shown promising results in using statins for cardiovascular risk reduction, making this approach both relevant and potentially impactful.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Grinspoon, Steven K. — Massachusetts General Hospital
- Study coordinator: Grinspoon, Steven K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.